Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NGEN

NervGen Pharma Corp

Feb 27 • 04:00PM ET

3.92

-0.26 -6.22 %

Healthcare • Biotechnology • Canada • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	21.50%	Shs Outstand	73.41M	Perf Week	-11.91%
Market Cap	311.99M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	62.48M	Perf Month	-9.26%
Enterprise Value	303.82M	PEG	-	EPS next Q	-0.04	Inst Own	0.06%	Short Float	2.10%	Perf Quarter	25.64%
Income	-18.50M	P/S	-	EPS this Y	29.46%	Inst Trans	-2.88%	Short Ratio	8.55	Perf Half Y	62.66%
Sales	0.00M	P/B	-	EPS next Y	-31.49%	ROA	-142.21%	Short Interest	1.31M	Perf YTD	-30.00%
Book/sh	-0.03	P/C	38.09	EPS next 5Y	1.68%	ROE	-790.82%	52W High	6.30 -37.78%	Perf Year	106.32%
Cash/sh	0.10	P/FCF	-	EPS past 3/5Y	-0.24% 1.73%	ROIC	-	52W Low	1.50 161.33%	Perf 3Y	164.86%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.07% 6.88%	Perf 5Y	124.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.53%	Oper. Margin	-	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.84	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	0.79	EPS Q/Q	24.68%	SMA20	-4.97%	Beta	0.89	Target Price	6.14
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-17.52%	Rel Volume	1.16	Prev Close	4.18
Employees	-	LT Debt/Eq	-	Earnings	Nov 25 BMO	SMA200	18.02%	Avg Volume	153.78K	Price	3.92
IPO	Apr 03, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.10% -	Trades		Volume	177,757	Change	-6.22%

Feb-18-26 07:30AM	NervGen Pharma to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-12-26 04:15PM	NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams (GlobeNewswire)
Feb-11-26 07:00AM	NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium (GlobeNewswire)
Feb-09-26 07:00AM	NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury (GlobeNewswire)
Jan-20-26 07:00AM	NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing (GlobeNewswire) -6.93%
06:30AM	Loading…
Jan-08-26 06:30AM	NervGen Pharma Begins Trading on Nasdaq Today (GlobeNewswire)

NervGen Pharma Corp. operates as a clinical stage biotech company. It provides development of treatment that enables the nervous system to repair itself following damage, whether due to injury or disease. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGEN

NervGen Pharma Corp

Upgrade your FINVIZ experience